SG163508A1 - Heterocyclic aspartyl protease inhibitors - Google Patents
Heterocyclic aspartyl protease inhibitorsInfo
- Publication number
- SG163508A1 SG163508A1 SG201004193-7A SG2010041937A SG163508A1 SG 163508 A1 SG163508 A1 SG 163508A1 SG 2010041937 A SG2010041937 A SG 2010041937A SG 163508 A1 SG163508 A1 SG 163508A1
- Authority
- SG
- Singapore
- Prior art keywords
- disclosed
- methods
- aspartyl protease
- protease inhibitors
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52953503P | 2003-12-15 | 2003-12-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG163508A1 true SG163508A1 (en) | 2010-08-30 |
Family
ID=34700000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG201004193-7A SG163508A1 (en) | 2003-12-15 | 2004-12-13 | Heterocyclic aspartyl protease inhibitors |
Country Status (28)
Country | Link |
---|---|
EP (4) | EP2153832B1 (ru) |
JP (4) | JP5020638B2 (ru) |
KR (1) | KR101259181B1 (ru) |
CN (3) | CN1913886B (ru) |
AR (1) | AR047050A1 (ru) |
AU (1) | AU2004299040A1 (ru) |
BR (1) | BRPI0417697A (ru) |
CA (1) | CA2548388A1 (ru) |
DK (1) | DK1699455T3 (ru) |
EC (2) | ECSP066640A (ru) |
ES (1) | ES2421527T3 (ru) |
HK (1) | HK1090847A1 (ru) |
HR (1) | HRP20130664T1 (ru) |
IL (1) | IL176236A (ru) |
MX (1) | MXPA06006730A (ru) |
MY (2) | MY148233A (ru) |
NO (1) | NO20063294L (ru) |
NZ (2) | NZ593012A (ru) |
PE (1) | PE20051048A1 (ru) |
PL (1) | PL1699455T3 (ru) |
PT (1) | PT1699455E (ru) |
RS (1) | RS52883B (ru) |
RU (1) | RU2405774C9 (ru) |
SG (1) | SG163508A1 (ru) |
SI (1) | SI1699455T1 (ru) |
TW (2) | TWI360542B (ru) |
WO (1) | WO2005058311A1 (ru) |
ZA (1) | ZA200604833B (ru) |
Families Citing this family (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763609B2 (en) * | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) * | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
JP2008503459A (ja) * | 2004-06-16 | 2008-02-07 | ワイス | β−セクレターゼを阻害するためのアミノ−5,5−ジフェニルイミダゾロン誘導体 |
KR20070026811A (ko) | 2004-06-16 | 2007-03-08 | 와이어쓰 | 베타-세크리타제 억제제로서의 디페닐이미다조피리미딘 및디페닐이미다졸 아민 |
RU2440993C2 (ru) * | 2004-10-07 | 2012-01-27 | Вайти Фармасьютикл, Инк. | Диаминоалкановые ингибиторы аспарагиновой протеазы |
AU2006205127A1 (en) | 2005-01-14 | 2006-07-20 | Wyeth | Amino-imidazolones for the inhibition of beta-secretase |
EP1844035A1 (en) | 2005-02-01 | 2007-10-17 | Wyeth | Amino-pyridines as inhibitors of beta-secretase |
EP1848692A1 (en) | 2005-02-14 | 2007-10-31 | Wyeth | AZOLYLACYLGUANIDINES AS ß-SECRETASE INHIBITORS |
JP2008543841A (ja) * | 2005-06-14 | 2008-12-04 | シェーリング コーポレイション | 大環状複素環式アスパルチルプロテアーゼインヒビター |
KR20080029965A (ko) | 2005-06-14 | 2008-04-03 | 쉐링 코포레이션 | 아스파르틸 프로테아제 억제제 |
CA2610812A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
WO2006138230A2 (en) * | 2005-06-14 | 2006-12-28 | Schering Corporation | The preparation and use of protease inhibitors |
EP1891021B1 (en) | 2005-06-14 | 2019-01-23 | Merck Sharp & Dohme Corp. | Aspartyl protease inhibitors |
JP4896972B2 (ja) * | 2005-06-14 | 2012-03-14 | シェーリング コーポレイション | 複素環式アスパルチルプロテアーゼ阻害剤、その調製及び使用 |
BRPI0613578A2 (pt) * | 2005-06-30 | 2012-01-17 | Wyeth Corp | composito da fórmula i; uso de um composto de fórmula i; e composição farmacêutica |
TW200738683A (en) * | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
TW200730523A (en) * | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
RU2008106936A (ru) | 2005-09-26 | 2009-11-10 | Вайет (Us) | Соединения амино-5-[4-(дифторметокси)фенил]-5-фенилимидазолона для ингибирования бета-секретазы |
EP2597087B1 (en) | 2005-10-25 | 2016-03-30 | Shionogi&Co., Ltd. | Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors |
JP2009513656A (ja) | 2005-10-27 | 2009-04-02 | シェーリング コーポレイション | 複素環式アスパルチルプロテアーゼインヒビター |
CA2628264A1 (en) * | 2005-10-31 | 2007-05-10 | Schering Corporation | Aspartyl protease inhibitors |
WO2007058580A1 (en) * | 2005-11-15 | 2007-05-24 | Astrazeneca Ab | Novel 2-aminopyrimidinone derivatives and their use |
TW200734311A (en) * | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
EP1954682A4 (en) * | 2005-11-21 | 2011-11-09 | Astrazeneca Ab | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT FOR USE IN THE TREATMENT OF COGNITIVE DEFICIENCY, ALZHEIMER'S DISEASE, NEURODEGENERATION AND DEMENTIA |
AR058381A1 (es) * | 2005-12-19 | 2008-01-30 | Astrazeneca Ab | Compuestos derivados de 2-aminopiridin-4-onas y una composicion farmaceutica |
BRPI0620025A2 (pt) * | 2005-12-19 | 2011-10-25 | Wyeth Corp | composto, método para o tratamento de uma doença ou transtorno associado a atividade excessiva de bace, método para modular a atividade de bace, composição farmacêutica e uso do composto |
WO2007100536A1 (en) | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
JP5191155B2 (ja) * | 2006-03-27 | 2013-04-24 | 大塚製薬株式会社 | カルボスチリル化合物からなる医薬 |
CN101460480A (zh) * | 2006-04-05 | 2009-06-17 | 阿斯利康(瑞典)有限公司 | 2-氨基嘧啶-4-酮类化合物及其用于治疗或预防Aβ相关病理的用途 |
US8168641B2 (en) * | 2006-06-12 | 2012-05-01 | Schering Corporation | Aspartyl protease inhibitors |
TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
US7700606B2 (en) | 2006-08-17 | 2010-04-20 | Wyeth Llc | Imidazole amines as inhibitors of β-secretase |
WO2008063114A1 (en) * | 2006-11-20 | 2008-05-29 | Astrazeneca Ab | Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia |
MX2009006228A (es) | 2006-12-12 | 2009-06-22 | Schering Corp | Inhibidores de aspartil proteasa. |
TW200831091A (en) * | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
WO2008076043A1 (en) * | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Novel 2-amino-5,5-diaryl-imidazol-4-ones |
TW200831484A (en) * | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
PE20090617A1 (es) | 2007-03-23 | 2009-05-08 | Wyeth Corp | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa |
JP5383483B2 (ja) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | アルツハイマー症治療用医薬組成物 |
EP2147914B1 (en) | 2007-04-24 | 2014-06-04 | Shionogi&Co., Ltd. | Aminodihydrothiazine derivatives substituted with cyclic groups |
TW200902503A (en) * | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
CN101848897A (zh) | 2007-09-06 | 2010-09-29 | 先灵公司 | γ分泌酶调节剂 |
MX2010005028A (es) | 2007-11-05 | 2010-05-27 | Schering Corp | Moduladores de gamma secretasa. |
CN101945868A (zh) | 2007-12-11 | 2011-01-12 | 先灵公司 | γ分泌酶调节剂 |
AU2009205072C1 (en) | 2008-01-18 | 2016-10-13 | Eisai R & D Management Co., Ltd. | Condensed aminodihydrothiazine derivative |
AU2009239536C1 (en) | 2008-04-22 | 2012-12-13 | Merck Sharp & Dohme Corp. | Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use |
CA2727859C (en) | 2008-06-13 | 2016-11-01 | Shionogi & Co., Ltd. | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY |
CN102105475B (zh) | 2008-07-28 | 2014-04-09 | 卫材R&D管理有限公司 | 螺氨基二氢噻嗪衍生物 |
WO2010013302A1 (ja) * | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
EP2324032B1 (en) | 2008-08-19 | 2014-10-01 | Vitae Pharmaceuticals, Inc. | Inhibitors of beta-secretase |
ES2459195T3 (es) | 2008-09-11 | 2014-05-08 | Amgen Inc. | Compuestos de anillo espiro-tetracíclico como moduladores de beta-secretasa y métodos de uso |
US8198269B2 (en) | 2008-09-30 | 2012-06-12 | Eisai R&D Management Co., Ltd. | Fused aminodihydrothiazine derivative |
JPWO2010047372A1 (ja) | 2008-10-22 | 2012-03-22 | 塩野義製薬株式会社 | Bace1阻害活性を有する2−アミノピリミジン−4−オンおよび2−アミノピリジン誘導体 |
CA2742486A1 (en) | 2008-11-13 | 2010-05-20 | Schering Corporation | Gamma secretase modulators |
TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
MX2011009571A (es) | 2009-03-13 | 2011-10-19 | Boehringer Ingelheim Int | Inhibidores de beta-secretasa. |
US20120015961A1 (en) | 2009-03-31 | 2012-01-19 | Shionogi & Co., Ltd. | Isothiourea derivatives or isourea derivatives having bace1 inhibitory activity |
US20120232108A1 (en) | 2009-06-16 | 2012-09-13 | Xianhai Huang | Gamma secretase modulators |
GB0912777D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydropyrimidone derivatives |
GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
EP2281824A1 (en) | 2009-08-07 | 2011-02-09 | Noscira, S.A. | Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
US8557826B2 (en) | 2009-10-08 | 2013-10-15 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use |
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
US8569310B2 (en) | 2009-10-08 | 2013-10-29 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions and their use |
US20120245155A1 (en) | 2009-12-11 | 2012-09-27 | Shionogi & Co., Ltd. | Fused heterocyclic compound having amino group |
ES2590038T5 (es) | 2009-12-11 | 2021-10-19 | Shionogi & Co | Derivado de oxazina |
JP5828848B2 (ja) * | 2010-02-24 | 2015-12-09 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | ベータセクレターゼインヒビター |
EP2547685A1 (en) | 2010-03-15 | 2013-01-23 | Amgen Inc. | Spiro-tetracyclic ring compounds as beta - secretase modulators |
CA2791389C (en) | 2010-03-15 | 2014-04-29 | Amgen Inc. | Amino -dihydrooxazine and amino - dihydrothiazine spiro compounds as beta - secretase modulators and their medical use |
EP2601197B1 (en) | 2010-08-05 | 2014-06-25 | Amgen Inc. | Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use |
AU2011321427A1 (en) | 2010-10-29 | 2013-05-02 | Shionogi & Co., Ltd. | Naphthyridine derivative |
JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
JP2013542973A (ja) | 2010-11-22 | 2013-11-28 | ノスシラ、ソシエダッド、アノニマ | 神経変性疾患または神経変性状態を治療するためのビピリジンスルホンアミド誘導体 |
US8957083B2 (en) | 2010-11-23 | 2015-02-17 | Amgen Inc. | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use |
GB201100181D0 (en) | 2011-01-06 | 2011-02-23 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
GB201101139D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
EP2665716B1 (en) | 2011-01-21 | 2017-03-08 | Eisai R&D Management Co., Ltd. | Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives |
GB201101140D0 (en) | 2011-01-21 | 2011-03-09 | Eisai Ltd | Fused aminodihydrothiazine derivatives |
WO2012109165A1 (en) | 2011-02-07 | 2012-08-16 | Amgen Inc. | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use |
US8962859B2 (en) | 2011-02-15 | 2015-02-24 | Amgen Inc. | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use |
EP2694521B1 (en) | 2011-04-07 | 2015-11-25 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
US9221839B2 (en) | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
TW201247635A (en) | 2011-04-26 | 2012-12-01 | Shionogi & Co | Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them |
JP2014524472A (ja) * | 2011-08-22 | 2014-09-22 | メルク・シャープ・アンド・ドーム・コーポレーション | Bace阻害剤としての2−スピロ置換イミノチアジンならびにそのモノオキシドおよびジオキシド、組成物、ならびにそれらの使用 |
US9296759B2 (en) | 2011-09-21 | 2016-03-29 | Amgen Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
TWI557112B (zh) | 2012-03-05 | 2016-11-11 | 百靈佳殷格翰國際股份有限公司 | β-分泌酶抑制劑 |
CA2867891C (en) | 2012-03-19 | 2021-09-14 | Buck Institute For Research On Aging | App specific bace inhibitors (asbis) and uses thereof |
GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
CN104394862A (zh) | 2012-05-30 | 2015-03-04 | 科门蒂斯公司 | 色满化合物 |
TW201422592A (zh) | 2012-08-27 | 2014-06-16 | Boehringer Ingelheim Int | β-分泌酶抑制劑 |
US9290477B2 (en) | 2012-09-28 | 2016-03-22 | Vitae Pharmaceuticals, Inc. | Inhibitors of β-secretase |
EP2908824B1 (en) | 2012-10-17 | 2018-05-02 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
US9422277B2 (en) | 2012-10-17 | 2016-08-23 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use |
US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
US9725469B2 (en) | 2012-11-15 | 2017-08-08 | Amgen, Inc. | Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use |
US9489013B2 (en) | 2012-12-20 | 2016-11-08 | Merck Sharp & Dohme Corp. | C6-azaspiro iminothiadiazine dioxides as bace inhibitors, compositions, and their use |
EP2934534B1 (en) | 2012-12-21 | 2017-12-13 | Merck Sharp & Dohme Corp. | C5-spiro iminothiadiazine dioxides as bace inhibitors |
ES2769578T3 (es) | 2013-02-12 | 2020-06-26 | Buck Inst Res Aging | Hidantoínas que modulan el procesamiento de APP mediado por BACE |
ES2612982T3 (es) * | 2013-02-25 | 2017-05-19 | Merck Patent Gmbh | Derivados de 2-amino-3,4-dihidroquinazolina y su aplicación como inhibidores de la catepsina D |
CA2902212C (en) | 2013-03-01 | 2020-10-13 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
JP6374889B2 (ja) | 2013-03-08 | 2018-08-15 | アムジエン・インコーポレーテツド | β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合1,3−オキサジン−2−アミン化合物、及び使用方法 |
EP2968357B1 (en) | 2013-03-15 | 2018-07-04 | Merck Sharp & Dohme Corp. | S-imino-s-oxo iminothiazine compounds as bace inhibitors, compositions, and their use |
US9428476B2 (en) | 2013-03-15 | 2016-08-30 | Merck Sharp & Dohme Corp. | S-imino-S-oxo-iminothiadiazine compounds as BACE inhibitors, compositions, and their use |
CA2914263C (en) * | 2013-06-21 | 2021-05-18 | Takeda Pharmaceutical Company Limited | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors |
WO2015038446A1 (en) | 2013-09-13 | 2015-03-19 | Merck Sharp & Dohme Corp. | C5-spiro iminothiazine dioxides as bace inhibitors, compositions, and their use |
WO2015095011A1 (en) | 2013-12-17 | 2015-06-25 | Janssen Pharmaceutica Nv | Imidazolin-5-one derivative useful as fasn inhibitors for the treatment of cancer |
WO2015095104A1 (en) | 2013-12-18 | 2015-06-25 | Merck Sharp & Dohme Corp. | Iminothiadiazepane dioxide compounds as bace inhibitors, compositions, and their use |
WO2015094930A1 (en) | 2013-12-18 | 2015-06-25 | Merck Sharp & Dohme Corp. | C-6 spirocarbocyclic iminothiadiazine dioxides as bace inhibitors, compositions, and their use |
CN106795147B (zh) | 2014-08-08 | 2020-09-22 | 美国安进公司 | 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法 |
ES2942308T3 (es) * | 2015-04-21 | 2023-05-31 | Allgenesis Biotherapeutics Inc | Compuestos y su uso como inhibidores de BACE1 |
CN105175488A (zh) * | 2015-09-07 | 2015-12-23 | 西北农林科技大学 | 一种具有抗老年痴呆症活性的化合物及其制备方法 |
CN108290860B (zh) | 2015-11-25 | 2021-08-10 | Ucb生物制药有限责任公司 | 作为plasmepsin v抑制剂的亚氨基四氢嘧啶酮衍生物 |
CN106749033A (zh) * | 2015-11-25 | 2017-05-31 | 中国人民解放军军事医学科学院毒物药物研究所 | 乙内酰脲类化合物及其作为β-分泌酶抑制剂的用途 |
GB201603104D0 (en) | 2016-02-23 | 2016-04-06 | Ucb Biopharma Sprl | Therapeutic agents |
JP6504106B2 (ja) * | 2016-04-21 | 2019-04-24 | 三菱電機ビルテクノサービス株式会社 | エレベータ装置 |
CA3034211A1 (en) | 2016-08-18 | 2018-02-22 | Vidac Pharma Ltd. | Piperazine derivatives, pharmaceutical compositions and methods of use thereof |
CN107892697B (zh) | 2016-12-26 | 2020-11-03 | 郑州泰基鸿诺医药股份有限公司 | 一种[1,3]噻嗪-2-胺类化合物及应用,药物组合物 |
JOP20180092A1 (ar) | 2017-10-13 | 2019-04-13 | Gilead Sciences Inc | مثبطات hiv بروتياز |
GB201805816D0 (en) | 2018-04-06 | 2018-05-23 | Ucb Biopharma Sprl | Therapeutic agents |
TW202104210A (zh) | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
GB201906804D0 (en) | 2019-05-14 | 2019-06-26 | Ucb Biopharma Sprl | Therapeutic agents |
CN114206856A (zh) | 2019-08-19 | 2022-03-18 | Ucb生物制药有限责任公司 | 抗疟疾的六氢嘧啶类似物 |
GB202010606D0 (en) | 2020-07-10 | 2020-08-26 | Ucb Biopharma Sprl | Therapeutic agents |
CN112010836B (zh) * | 2020-09-07 | 2021-07-09 | 南通大学 | 含芳基联吡啶氧基结构的2-取代基咪唑烷衍生物及其制备方法和用途 |
WO2023152042A1 (en) | 2022-02-08 | 2023-08-17 | UCB Biopharma SRL | Antimalarial hexahydropyrimidine analogues |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH511863A (de) * | 1967-04-13 | 1971-08-31 | Ciba Geigy Ag | Verfahren zur Herstellung von 2,4-Benzdiazepinen |
DE2448869A1 (de) * | 1973-10-19 | 1975-09-04 | Mcneilab Inc | 4-oxo-2-imidazolidinylidenharnstoffe, verfahren zu ihrer herstellung und arzneimittel |
IL92011A0 (en) * | 1988-10-19 | 1990-07-12 | Abbott Lab | Heterocyclic peptide renin inhibitors |
PL328223A1 (en) * | 1996-01-26 | 1999-01-18 | Vertex Pharma | Aspartil protease inhibitors |
AU2012199A (en) * | 1997-12-24 | 1999-07-19 | Vertex Pharmaceuticals Incorporated | Prodrugs of aspartyl protease inhibitors |
US6436989B1 (en) * | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
EP1159278B1 (en) * | 1999-02-12 | 2005-11-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of aspartyl protease |
EP1189609A4 (en) * | 1999-05-03 | 2002-10-30 | Smithkline Beecham Corp | CXCR-4 RECEPTOR ANTAGONISTS AND THROMBOPOIETIN MIMETIKA |
AR031520A1 (es) * | 1999-06-11 | 2003-09-24 | Vertex Pharma | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion |
US7560482B2 (en) | 2001-03-15 | 2009-07-14 | The Johns Hopkins University | Inhibitors of plasmepsins |
-
2004
- 2004-12-13 AU AU2004299040A patent/AU2004299040A1/en not_active Abandoned
- 2004-12-13 PL PL04813947T patent/PL1699455T3/pl unknown
- 2004-12-13 MY MYPI2010004561A patent/MY148233A/en unknown
- 2004-12-13 EP EP09174520.8A patent/EP2153832B1/en active Active
- 2004-12-13 NZ NZ593012A patent/NZ593012A/xx not_active IP Right Cessation
- 2004-12-13 CN CN2004800415165A patent/CN1913886B/zh not_active Expired - Fee Related
- 2004-12-13 CA CA002548388A patent/CA2548388A1/en not_active Abandoned
- 2004-12-13 WO PCT/US2004/041700 patent/WO2005058311A1/en active Application Filing
- 2004-12-13 KR KR1020067011805A patent/KR101259181B1/ko not_active IP Right Cessation
- 2004-12-13 CN CN200910163552.3A patent/CN101671307B/zh not_active Expired - Fee Related
- 2004-12-13 SG SG201004193-7A patent/SG163508A1/en unknown
- 2004-12-13 ES ES04813947T patent/ES2421527T3/es active Active
- 2004-12-13 RU RU2006125377/04A patent/RU2405774C9/ru not_active IP Right Cessation
- 2004-12-13 JP JP2006544081A patent/JP5020638B2/ja not_active Expired - Fee Related
- 2004-12-13 EP EP10183357A patent/EP2335701B1/en active Active
- 2004-12-13 PT PT48139471T patent/PT1699455E/pt unknown
- 2004-12-13 EP EP04813947.1A patent/EP1699455B1/en active Active
- 2004-12-13 BR BRPI0417697-9A patent/BRPI0417697A/pt not_active IP Right Cessation
- 2004-12-13 SI SI200432060T patent/SI1699455T1/sl unknown
- 2004-12-13 DK DK04813947.1T patent/DK1699455T3/da active
- 2004-12-13 CN CN201210089893.2A patent/CN102627609B/zh not_active Expired - Fee Related
- 2004-12-13 NZ NZ547462A patent/NZ547462A/en not_active IP Right Cessation
- 2004-12-13 MX MXPA06006730A patent/MXPA06006730A/es active IP Right Grant
- 2004-12-13 RS RS20130328A patent/RS52883B/en unknown
- 2004-12-13 EP EP10183450.5A patent/EP2343069B1/en active Active
- 2004-12-13 MY MYPI20045132A patent/MY149978A/en unknown
- 2004-12-14 AR ARP040104647A patent/AR047050A1/es unknown
- 2004-12-14 TW TW098126875A patent/TWI360542B/zh not_active IP Right Cessation
- 2004-12-14 TW TW093138776A patent/TWI354666B/zh not_active IP Right Cessation
-
2005
- 2005-01-03 PE PE2005000018A patent/PE20051048A1/es not_active Application Discontinuation
-
2006
- 2006-06-11 IL IL176236A patent/IL176236A/en not_active IP Right Cessation
- 2006-06-12 ZA ZA200604833A patent/ZA200604833B/xx unknown
- 2006-06-14 EC EC2006006640A patent/ECSP066640A/es unknown
- 2006-07-14 NO NO20063294A patent/NO20063294L/no not_active Application Discontinuation
- 2006-10-23 HK HK06111641.4A patent/HK1090847A1/xx not_active IP Right Cessation
-
2008
- 2008-03-25 JP JP2008079293A patent/JP2008174570A/ja active Pending
-
2011
- 2011-04-01 JP JP2011082314A patent/JP5316999B2/ja not_active Expired - Fee Related
-
2012
- 2012-01-19 EC EC2012006640A patent/ECSP12006640A/es unknown
- 2012-02-20 JP JP2012034364A patent/JP2012097122A/ja active Pending
-
2013
- 2013-07-11 HR HRP20130664TT patent/HRP20130664T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG163508A1 (en) | Heterocyclic aspartyl protease inhibitors | |
WO2006065277A3 (en) | Heterocyclic aspartyl protease inhibitors | |
SG162790A1 (en) | Aspartyl protease inhibitors | |
WO2006138230A3 (en) | The preparation and use of protease inhibitors | |
TW200716567A (en) | Aspartyl protease inhibitors | |
WO2006138266A3 (en) | The preparation and use of compounds as aspartyl protease inhibitors | |
TW200716644A (en) | Aspartyl protease inhibitors | |
WO2007146225A3 (en) | Heterocyclic aspartyl protease inhibitors | |
WO2006138265A3 (en) | Heterocyclic aspartyl protease inhibitors, preparation and use thereof | |
MX2009006227A (es) | Inhibidores de aspartil proteasa que contienen un sistema de anillo triciclico. | |
MX2009006228A (es) | Inhibidores de aspartil proteasa. | |
WO2007050721A3 (en) | Heterocyclic aspartyl protease inhibitors | |
CA2678958C (en) | Heterocyclic aspartyl protease inhibitors | |
MX2007016185A (es) | Inhibidores de aspartil proteasa heterociclicos macrociclicos. | |
IL165262A (en) | Kinase inhibitors and pharmaceutical compositions containing them | |
WO2005021584A3 (en) | Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus | |
WO2005025554A3 (en) | Dipeptidyl peptidase iv inhibitor | |
MX2009014208A (es) | Compuestos heterociclicos y usos de los mismos como inhibidores de erk. | |
WO2005032472A3 (en) | Pyrrolidine and piperidine derivatives as factor xa inhibitors | |
WO2001064639A3 (en) | Pde iv inhibiting amides, compositions and pharmaceutical use | |
MA28170A1 (fr) | Nouveaux derives de ceto-oxadiazole comme inhibiteurs de la cathepsine | |
WO2004010937A3 (en) | Method of treating cancer | |
DE60322417D1 (en) | 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1,8-naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren | |
WO2004103278A3 (en) | Acyl sulfonamides as inhibitors of hiv integrase | |
MY145415A (en) | Method and apparatus for manufacturing ophthalmic lenses |